The Almac Group is an established CDMO providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. We have a global reputation for excellence built over 50 years of client service delivering expertise across the drug development lifecycle offering a tailored solution to our clients. Almac Sciences provides drug development services (small molecules & peptides) with expertise in small and large molecule analytics, API supply, stable & 14C radiolabelling, formulation development & solid-state services. Almac provide a full suite of analytical testing services across 3 FDA approved laboratories. Encompassing method development, validation, transfer and stability studies on small molecule, biologics, active ingredients and finished products (including controlled substances). Almac’s team of 170 analysts have the capacity and capability to deliver your project. In 2020 Almac announced the expansion of its existing suite of analytical solutions to include biologics testing. The biologic analytical services Almac can provide include GMP release and stability testing to support clients’ drug substance and drug product programs for both novel biologics and biosimilars; fit-for-purpose analytical method development / phase-appropriate method validation; raw material testing for microbial and mammalian expression systems that comply with pharmacopeial requirements.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.